A proposed ban on direct-to-consumer prescription drug advertising could spell trouble for the industry's biggest ad spender.
Big names are promising big plays in hepatitis C cures
Digging into recent announcements that could impact the marijuana and hepatitis C markets next year.
Bristol-Myers Squibb, Pfizer, and AbbVie Inc. market some of the fastest-growing cancer drugs on the market.
An updated investor presentation appears to have bulls excited, and shares are soaring today as a result.
Are you on the hunt for a strong dividend payer? Our contributors think these five names deserve a hard look.
Cempra's stock sells off hard on good news. Is the stock now a bargain?
The patent cliff crushed these Big Pharma companies, and now their only opportunity for sustainable growth might be to go shopping for a rival.
This simple fundamental metric says you might be overpaying for shares of most Big Pharma stocks.
The markets have been on a roller coaster-like ride over the past few weeks. Here are five dividend stocks that could anchor your portfolio during these turbulent times.